Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

NCT05800665 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05800665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05800665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 2, 2023
Completion date
June 30, 2027
Enrollment
210 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer, metastatic prostate cancer